MedTrace Logo

Apolipoprotein D (ApoD) In Human Serum As Marker Of Parkinson's Disease

NCT01467960 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 180

Last updated 2013-10-30

Study results available
· View outcomes & findings →

Summary

In Italy affected people are 200,000 and every year Parkinson new cases are 10,000. Aging is the principle risk factor of Parkinson with the possibility of its development doubling every five years after 65. Because of the increase of the social longevity and aging as the main risk factor, there are many repercussions on the health system (hospital stays and pharmaceutical costs) as on the social system (assistance- related problems). Parkinson's disease exerts an extremely negative impact on life's quality of the patient. In fact, because of Parkinson symptoms (tremor, dribble, etc), patient's social life will be reduced with the consequent development of the depression. Consequently, the early detection and treatment of Parkinson's is necessary.

To achieve this goal, Apolipoprotein D (ApoD) in human serum as a marker of the oxidative stress-inflammation vicious cycle seems most promising candidate for diagnosis.

Conditions

Sponsors & Collaborators

  • Privatklinik Villa Melitta

    lead OTHER

Principal Investigators

  • Andreas Waldner, MD · Privatklinik Villa Melitta

  • Sarah Dassati, BSc · Privatklinik Villa Melitta

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2011-11-30
Primary Completion
2013-06-30
Completion
2013-11-30

Countries

  • Italy

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01467960 on ClinicalTrials.gov